Oxygen Single Bonded To A Ring Carbon Of The Cyclopentanohydrophenanthrene Ring System Patents (Class 514/178)
-
Publication number: 20100152146Abstract: Pharmaceutical preparations for topical or local administration of drugs directly to the skin for treatment of disorders of the subcutaneous fatty tissue, in particular in cases of cellulite, are disclosed herein. In a preferred embodiment, the drug is danazol or gastrinone. In another embodiment, the drug is danazol in combination with an aromatase inhibitor or an estrogen compound. The preferred formulations contain drugs in the form of micro or nanoparticles, which may be formed of drug alone or in combination with an excipient or carrier. The excipient or carrier may modify the release rates or enhance absorption into the affected area. The drug formulation may be in the form of a cream, lotion, ointment, gel or emulsion, solution or foam.Type: ApplicationFiled: February 25, 2010Publication date: June 17, 2010Inventors: Paul Dmowski, Gerianne T. DiPiano
-
Publication number: 20100151002Abstract: The present invention relates to the methods for preparing synthetic guggulphospholipids, their fatty acid analogues and other bioactive molecules. The present invention relates to E-guggulsterone and Z-guggulsterone or mixture of E- and Z-guggulsterones. The present invention also provides a novel method for the preparation of E-guggulsterol and Z-guggulsterol or mixture of E- and Z-guggulsterols from a mixture of E- and Z-guggulsterones. The present invention further relates to guggulphospholipids and other bioactive molecules incorporated into complexes such as liposomes, complexes, emulsions, vesicles, micelles, and mixed micelles, which can include other active agents, such as hydrophobic or hydrophilic drugs for use, e.g., in treatment of human and animal diseases.Type: ApplicationFiled: November 6, 2007Publication date: June 17, 2010Applicant: JINA PHARMACEUTICALS, INC.Inventors: Moghis U. Ahmad, Shoukath M. Ali, Ateeq Ahmad, Saifuddin Sheikh, Imran Ahmad
-
Patent number: 7732493Abstract: The invention relates to new 2-substituted D-homo-estra-1,3,5(10)-trienes of general formula I in which R2 means a C1-C8-alkyl group, a C1-C8-alkyloxy group or a halogen atom, R13 means a hydrogen atom or a methyl group, R17 means a hydrogen atom or a fluorine atom, as well as their pharmaceutically acceptable salts, their manufacture and use as medicaments for prophylaxis and therapy of estrogen-dependent diseases that can be influenced by inhibition of 17?-hydroxy steroid dehydro-genase type 1.Type: GrantFiled: August 15, 2008Date of Patent: June 8, 2010Assignee: Bayer Schering Pharma AktiengesellschaftInventors: Alexander Hillisch, Olaf Peters, Christian Gege, Wilko Regenhardt, Gabriele Moeller, Dominga Deluca, Jerzy Adamski, Walter Elger, Birgitt Schneider
-
Patent number: 7732432Abstract: The present invention encompasses compounds of Formula (I) or pharmaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included.Type: GrantFiled: January 16, 2004Date of Patent: June 8, 2010Assignee: Merck Sharp & Dohme Corp.Inventors: Amjad Ali, James M. Balkovec, Donald W. Graham, Mark L. Greenlee, Gayle E. Taylor
-
Publication number: 20100137271Abstract: Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs are provided. The pharmaceutical compositions include a therapeutically effective amount of a hydrophobic drug, preferably a steroid; a solubilizer, and a surfactant. The synergistic effect between the hydrophobic drug and the solubilizer results in a pharmaceutical formulation with improved dispersion of both the active agent and the solubilizer. As a result of the improved dispersion, the pharmaceutical composition has improved bioavailability upon administration. Methods of improving the bioavailability of hydrophobic drugs administered to a patient are also provided.Type: ApplicationFiled: November 24, 2009Publication date: June 3, 2010Applicant: LIPOCINE, INC.Inventors: FENG-JING CHEN, MAHESH V. PATEL, DAVID T. FIKSTAD, HUIPING ZHANG, CHANDRASHEKAR GILIYAR
-
Publication number: 20100135956Abstract: The present invention relates to new steroid modulators of progesterone receptor activity and/or glucocorticoid receptor activity, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: November 23, 2009Publication date: June 3, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Manouchehr Shahbaz
-
Publication number: 20100137270Abstract: A variety of diseases and disorders associated with the metabolic pathways involved in the activities of cyclooxygenase and the synthesis of prostaglandins, for example type 2 diabetes mellitus and its sequelae, ischemic vascular diseases, pain associated with inflammation, inflammatory skin conditions, spinal cord injury, peripheral neuropathy, multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis, as well as various types of cancer may be treated or prevented by the use of an agent which selectively enhances production of 15-deoxy-prostaglandin J2.Type: ApplicationFiled: November 29, 2007Publication date: June 3, 2010Applicant: Hunter-Fleming LimitedInventor: Ernst Wülfert
-
Publication number: 20100130459Abstract: 3-Hydroxy-7?-hydroxy steroids and 3-oxo-7?-hydroxy steroids and pharmaceutically acceptable estors thereof are useful for protection against neuronal damage.Type: ApplicationFiled: December 15, 2009Publication date: May 27, 2010Applicant: Hunter-Fleming LimitedInventors: Ernst Wülfert, Ashley Ker Pringle, Lars Eric Sundstrom
-
Patent number: 7718639Abstract: 7-Hydroxyepiandrosterone may be used for protection against acute or chronic neuronal damage.Type: GrantFiled: June 29, 2001Date of Patent: May 18, 2010Assignee: Hunter-Fleming LimitedInventors: Ernst Wulfert, Ashley Ker Pringle, Lars Eric Sundstrom
-
Publication number: 20100119595Abstract: The pharmaceutical and/or cosmetic compositions for treatment of obesity and/or overweight contain an effective amount of a fatty-acid monoester of a 2 hydroxy derivative estrogen and a fatty acid wherein the estrogen is preferably a 2 hydroxy derivative of estrone, diethylstilbestrol, estriol, estradiol or ethinyl estradiol and the fatty acid is selected from the group consisting of the fatty acid oleic acid, arachadonic, palmitic, palmitoleic, linoleic, linolenic, cis 13 docosenoic acid, and the fatty acid, cis 15 tetracosenoic acid eicosenoic acid, especially cis 11 eicosenoic, although cis 5, cis 8, and cis 13 eicosenoic acid are also effective. The C-22 fatty acid monoester of estrogen, cis to 13 docosenoic acid (Erucic acid), and the C-24 fatty acid monoester of estrogen, cis 15 tetracosenoic acid (Nervonic acid) are also effective and are included in this disclosure.Type: ApplicationFiled: October 1, 2009Publication date: May 13, 2010Inventor: Michael P. GIROUARD
-
Publication number: 20100113407Abstract: The present invention is directed to a method of using dehydroepiandrosterone (DHEA) to treat a human female with diminished ovarian reserve. The method includes measuring a baseline follicle stimulating hormone (FSH) level of the human female, and when the baseline FSH level is below about 40.0 mIU/ml, administering about 75 milligrams of DHEA per day to the female for at least four months to treat ovarian follicles in at least one ovary of the female to improve human folliculogenesis during the at least four months. The present invention further is directed to a method of restoring the ovarian environment of an older human female to that of a younger human female. The method includes administering about 75 milligrams of DHEA per day to the female for at least four months.Type: ApplicationFiled: October 30, 2009Publication date: May 6, 2010Applicant: American Infertility of New YorkInventors: Norbert Gleicher, David H. Barad, Dwyn V. Harben
-
Publication number: 20100113406Abstract: Disclosed are methods comprising administering a dosage form comprising a pharmaceutical carrier and at least one glucocorticoid to a subject suffering from congestive heart failure, wherein the at least one glucocorticoid is present in the dosage form in an amount effective to ameliorate aspects of the congestive heart failure. Also disclosed are related methods and dosage forms.Type: ApplicationFiled: March 14, 2008Publication date: May 6, 2010Inventors: Johannes J.R. Hermans, Jos F.M. Smits, Harry A.J. Struijker-Boudier, Monica Minnaard-Huiban
-
Patent number: 7709495Abstract: The invention features a method for treating an immunoinflammatory administering a compound of formula (I), e.g., ibudilast or KC-764, alone or in combination with a corticosteroid, tetra-substituted pyrimidopyrimidine, or other compound. The invention also features pharmaceutical compositions including the combination above for the treatment or prevention of an immunoinflammatory disorder.Type: GrantFiled: November 19, 2004Date of Patent: May 4, 2010Assignee: CombinatoRx, IncorporatedInventors: Edward Roydon Jost-Price, Palaniyandi Manivasakam, Brendan Smith, Michael S. Slavonic, Benjamin A. Auspitz
-
Publication number: 20100104506Abstract: Nanoparticle-coated medical devices, nanoparticle-containing formulations and methods of using for treating a vascular disease are disclosed. The medical device includes a coating that comprises a plurality of nanoparticles, wherein the nanoparticles comprise one or more bioactive agents encapsulated within, adhered to a surface of or integrated into the structure of the nanoparticles and further comprise one or more contrast enhancing agents encapsulated within, adhered to a surface of or integrated into the structure of the nanoparticles.Type: ApplicationFiled: January 5, 2010Publication date: April 29, 2010Applicant: Abbott Cardiovascular Systems Inc.Inventors: Florian Niklas Ludwig, Syed Faiyaz Ahmed Hossainy, Katsuyuki Murase, Li Zhao, Irina Astafieva
-
Patent number: 7696189Abstract: The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications.Type: GrantFiled: August 7, 2007Date of Patent: April 13, 2010Assignee: Hollis-Eden Pharmaceuticals, Inc.Inventor: James M. Frincke
-
Patent number: 7691835Abstract: The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications.Type: GrantFiled: August 7, 2007Date of Patent: April 6, 2010Assignee: Hollis-Eden Pharmaceuticals, Inc.Inventor: James M. Frincke
-
Publication number: 20100081640Abstract: A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic ketone; the use of the composition to treat a condition, for example, male hypogonadism, in a patient by applying the composition to the membrane of the patient; and a method for making the composition.Type: ApplicationFiled: September 30, 2009Publication date: April 1, 2010Applicant: CPEX PHARMACEUTICALS, INC.Inventor: Robert J. Gyurik
-
Patent number: 7687486Abstract: Compositions and methods for treating a cancer in mammals by administering selective estrogen receptor modulators particularly compounds represented by: or any other of the structures contained herein, or of a stereoisomer, enantiomer, rotomer, tautomer or pharmaceutically acceptable salt form thereof.Type: GrantFiled: March 5, 2005Date of Patent: March 30, 2010Assignee: Florida Agricultural & Mechanical UniversityInventor: John S. Cooperwood
-
Publication number: 20100075936Abstract: The invention provides the use of a glucocorticoid receptor antagonist for the manufacture of a medicament for immune stimulation, such as prevention or treatment of infections or infectious conditions, in an aging mammalian subject, a mammalian subject with low serum DHEAS values, a mammalian subject with a high serum cortisol/DHEAS ratio or a mammalian subject with high neutrophil counts. In particular, the glucocorticoid receptor antagonist can be chosen from the group consisting of a dibenzopyranyl derivative defined and/or exemplified in U.S. Pat. No. 6,329,534 and WO200116128, mifepristone, and (11?,17?)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one.Type: ApplicationFiled: August 6, 2007Publication date: March 25, 2010Inventor: Bernardus Wijnand Mathys Marie Peeters
-
Publication number: 20100069343Abstract: Methods are provided for determining in vitro whether or not a patient will respond to steroid treatment based on the levels of interleukin-1 receptor type II (IL-1RII) in a sample of mononuclear immune cells obtained from the patient before steroid treatment and/or on the change in IL-1RII in the patient's mononuclear immune cells in response to an in vitro steroid challenge.Type: ApplicationFiled: July 17, 2009Publication date: March 18, 2010Inventor: Andrea Vambutus
-
Publication number: 20100068181Abstract: The present invention provides compounds of Formula I (wherein R, R1, R3, R4, X, and ring Y are as defined herein). The present invention also provides compositions comprising these compounds that are useful for treating cellular proliferative diseases or disorders associated with KSP kinesin activity and for inhibiting KSP kinesin activity.Type: ApplicationFiled: December 19, 2007Publication date: March 18, 2010Inventors: Sunil Paliwal, Hon-Chung Tsui, Jose S. Duca, Charles A. Lesburg, Ronald J. Doll, Neng-Yang Shih
-
Publication number: 20100069316Abstract: The present invention provides methods of treating a subject suffering from multiple myeloma comprising administering to the subject an effect amount of a compound according to Formula I:Type: ApplicationFiled: November 27, 2007Publication date: March 18, 2010Inventors: Michel Jourdan, Michel Dreano, Bernard Klein
-
Publication number: 20100061975Abstract: The present invention relates to novel uses of 4,17?-dihydroxyandrost-4-ene-3-one (hereinafter 4-hydroxytestosterone), to a process for their preparation, to pharmaceutical compositions containing them, and to the use of said compounds for the prophylaxis and/or treatment of breast cancer in mammals irrespective of the estrogen-receptor status of the tumor.Type: ApplicationFiled: May 11, 2007Publication date: March 11, 2010Inventor: Alexander Tobias Teichmann
-
Publication number: 20100063014Abstract: The present invention relates to the use of at least one gestagen selected from the group consisting of chlormadinone acetate, 3?-hydroxy-6-chloro-17?-acetoxy-4,6-pregnadien-20-one (3?-hydroxy-chlormadinone acetate) and 3?-hydroxy-6-chloro-17?-acetoxy-4,6-pregnadien-20-one (3?-hydroxy-chlormadinone acetate) as gestagen component and optionally at least one oestrogen selected from the group consisting of ethinyl oestradiol, oestrone, oestriol as oestrogen component and oestradiol to produce a medicament for the treatment and/or prevention of melasma and optionally for simultaneous hormonal contraception or optionally for simultaneous hormone replacement for women.Type: ApplicationFiled: September 3, 2009Publication date: March 11, 2010Applicant: GRÜNENTHAL GMBHInventor: GEORG SCHRAMM
-
Patent number: 7674783Abstract: A method for preventing or treating vascular hyperreactivity in which a chemical compound that is an estrogen beta receptor agonist is administered to a subject suffering from or at risk of vascular hyperreactivity. Preferably, the administration is topically to the skin.Type: GrantFiled: October 21, 2003Date of Patent: March 9, 2010Assignee: Dimera Inc.Inventor: R. Kent Hermsmeyer
-
Publication number: 20100056444Abstract: NSC antagonists are disclosed as useful in the treatment of dementia, in delaying the onset of dementia, and in the prevention of dementia. Dementia so treated may be, for example, Alzheimer's Disease (AD). NSC antagonists for treating dementia such as AD may be administered alone, a) in combination with other drugs used for treating dementia, b) in combination with drugs that stabilize or increase blood plasma glucose levels, or with both a) and b). Pharmaceutical compositions, dosage forms, and methods for using the same are disclosed, which include NSC antagonists, NSC antagonists combined with dementia drugs, NSC antagonists combined with glucose-level stabilizing or enhancing drugs, or combinations of these. Dosage forms may be designed to provide stable plasma levels for extended periods of time.Type: ApplicationFiled: October 11, 2007Publication date: March 4, 2010Inventors: Sven Martin Jacobson, Robert Ang
-
Publication number: 20100055137Abstract: An oil in water microemulsion or sub-micron emulsion composition for dermal delivery of at least one pharmaceutically active ingredient, is provided. The composition includes an oil phase dispersed throughout a water phase, the oil phase including at least one member selected from the group consisting of an animal oil, a mineral oil, a vegetable oil, a silane member, a siloxane, an ester, a fatty acid, a fat, a halogen compound, and an alkoxylated alcohol; and at least one lipophilic surfactant, the water phase including at least one hydrophilic surfactant, water and optionally a non-surfactant amphiphilic compound, the weight ratio of the at least one hydrophilic surfactant to the at least one lipophilic surfactant being approximately 9.0:1.0 to 2.0:3.0.Type: ApplicationFiled: June 25, 2009Publication date: March 4, 2010Applicant: STIEFEL RESEARCH AUSTRALIA PTY LTDInventors: Maria Graziella Larm, Ronald Harding, Michael Johnston, Albert Zorko Abram, Prema Vijayakumar, Phoebe Sun
-
Publication number: 20100057047Abstract: A nasal delivery device for and method of delivering substance to the middle meatus in a nasal cavity of a subject in the treatment of a condition, in particular an inflammatory or infectious condition, thereof, the delivery device comprising: a nosepiece unit (17) including a nosepiece (20) for fitting to a nostril of a subject and a nozzle (25) through which substance is in use delivered to the respective nasal cavity; and a delivery unit (29) for delivering substance through the nozzle of the nosepiece; wherein the delivery device is configured to provide for deposition of a significant fraction of the delivered dose on, around and in the vicinity of the middle meatus.Type: ApplicationFiled: February 14, 2007Publication date: March 4, 2010Applicant: OptiNose ASInventors: Per Gisle Djupesland, Colin David Sheldrake, Roderick Peter Hafner
-
Patent number: 7671045Abstract: The present invention is directed to novel 17-phosphorous steroid derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by a progesterone or glucocorticoid receptor.Type: GrantFiled: February 16, 2007Date of Patent: March 2, 2010Assignee: Janssen Pharmaceutica N.V.Inventors: Weiqin Jiang, Zhihua Sui
-
Patent number: 7671044Abstract: The present invention refers to a pharmaceutical formulation characterized in that it includes mainly clobetasolpropionate, minoxidil and 11 alpha hydroxyprogesterone as main active principles, besides other excipients, vitamins and/or minerals, and to its use in the treatment of skin diseases, mainly in the symptomatic treatment of psoriasis.Type: GrantFiled: September 14, 2006Date of Patent: March 2, 2010Assignee: Klever Mode, S.L.Inventor: Enrique Rossell Barranco
-
Publication number: 20100048525Abstract: The present invention is directed to a method of improving ovarian reserve in a human female with diminished ovarian reserve as measured by the female's anti-Müllerian hormone level. The method may include evaluating a first anti-Müllerian hormone level of the female, administering dehydroepiandrosterone to the female for at least about one month, and evaluating a second anti-Müllerian hormone level of the female, wherein the second anti-Müllerian hormone level is greater than the first anti-Müllerian hormone level.Type: ApplicationFiled: October 7, 2009Publication date: February 25, 2010Inventors: Norbert GLEICHER, David H. Barad, Dwyn V. Harben
-
Publication number: 20100047195Abstract: A pharmaceutical composition for treating a lip condition. The pharmaceutical composition includes a therapeutically effective amount of a corticosteroid, or a physiologically acceptable salt of the corticosteroid, and a physiologically acceptable carrier In the composition, the corticosteroid does not include hydrocortisone. Also provided is a method of using the composition to treat a lip condition such as inflammation or infection.Type: ApplicationFiled: May 16, 2008Publication date: February 25, 2010Inventor: David Elbaum
-
Publication number: 20100048526Abstract: The present invention relates to a novel pharmaceutical composition for transdermal or transmucous administration of at least one active substance, and comprising especially a fatty acid as a percutaneous absorption promoter, at least one alcoholic vehicle and also a stabilizer capable of stabilizing the fatty acid in the said pharmaceutical composition.Type: ApplicationFiled: October 30, 2009Publication date: February 25, 2010Inventors: Brigitte Taravella, Valerie Masini-Eteve
-
Publication number: 20100041633Abstract: The invention relates to nitrooxyderivative of corticosteroids of general formula (I) and pharmaceutically acceptable salts or stereoisomers thereof wherein R is a corticosteroid residue selected from: The compounds are useful in the treatment of respiratory diseases.Type: ApplicationFiled: January 28, 2008Publication date: February 18, 2010Applicant: NICOX S.A.Inventors: Francesca Benedini, Stefano Biondi, Ennio Ongini
-
Publication number: 20100035793Abstract: Use of a composition that modulates a STAT in the manufacture of a medicament for treating or preventing a fibroproliferative disease. The fibroproliferative disease may comprise keloid scarring. The composition may modulate one or more of; activity; phosphorylation; level of expression; or sub-cellular localisation of the STAT. The STAT may be STAT 3.Type: ApplicationFiled: July 27, 2005Publication date: February 11, 2010Inventors: Cheh Peng Lim, Xinmin Cao, Ivor Jiun Lim, Toan-Thang Phan
-
Publication number: 20100035854Abstract: A dry powder suitable for inhalation in a dry powder inhaler, the powder comprising a carrier, an active agent and at least 0.5% by weight of magnesium stearate, the powder being further characterized in that the less than 10% of the surface of the carrier material is covered with particles of magnesium stearate. The invention is also directed to a method of making dry powders by blending together the ingredients mentioned in a diffusion blender for a period time that is less than 60 minutes.Type: ApplicationFiled: August 6, 2009Publication date: February 11, 2010Inventors: Rudi Mueller-Walz, Roland Steiner
-
Publication number: 20100034838Abstract: The present invention relates to compositions for transdermal administration of a therapeutic agent for providing a systemic therapeutic effect. In particular, the invention relates to spreadable compositions, or compositions which may be solid at a temperature of about 25° C. or less and have a softening point of not higher than 35° C., wherein transdermal administration of the therapeutic agent may be either rapid or sustained.Type: ApplicationFiled: December 7, 2006Publication date: February 11, 2010Inventors: John Staniforth, Paul Goggin
-
Publication number: 20100022494Abstract: A method, device, or kit is provided which maintain a substantially physiological level of one or more steroid hormones in a mammalian subject in need thereof. The method, device, or kit includes providing to the subject at least one treatment regimen including replacement therapy for the one or more steroid hormones or metabolites or modulators thereof, wherein the at least one treatment regimen is determined based on steroid hormone levels prior to disease diagnosis in the subject and on current steroid hormone levels in the subject, wherein the at least one treatment regimen is configured to maintain the subject's one or more steroid hormones or metabolites or modulators thereof at substantially physiological pre-disease levels. The method, device, or kit can be used for the treatment of a disease or condition in the mammalian subject.Type: ApplicationFiled: July 24, 2008Publication date: January 28, 2010Inventors: Roderick A. Hyde, Muriel Y. Ishikawa, Dennis J. Rivet, Elizabeth A. Sweeney, Lowell L. Wood, JR., Victoria Y.H. Wood
-
Publication number: 20100021475Abstract: Disclosed herein are compositions and methods for reducing the growth of hematopoietic malignant cells (e.g., B-cell leukemia cells). The methods involve reducing the growth of hematopoietic malignant cells by contacting hematopoietic malignant cells with GP88 antagonists. GP88 is an 88 KDa autocrine growth factor that promotes the growth of hematopoietic malignant cells. Antagonists to GP88 are provided which inhibit its expression or biological activity. The antagonists include antisense oligonucleotides and antibodies. Also provided are methods for determining if a patient is responding or is responsive to anti-cancer therapy (e.g., glucocorticoid therapy). Increased levels of GP88 in hematopoietic cells indicates a patient is not responding or responsive to anti-cancer therapy.Type: ApplicationFiled: April 8, 2009Publication date: January 28, 2010Applicant: A & G PHARMACEUTICAL, INC.Inventor: GINETTE SERRERO
-
Publication number: 20100015050Abstract: Provided are compositions of nanoparticles, PEG and targeting moieties. The compositions are useful in treating tumors, imaging the particles in tissues, and in targeting therapeutic agents to specific tissues and locations in a patient. Also provided are methods of preparing and methods of using the compositions.Type: ApplicationFiled: December 20, 2007Publication date: January 21, 2010Applicant: WAYNE STATE UNIVERSITYInventors: Jayanth Panyam, Yogesh Patil, Ayman Khdair
-
Publication number: 20100004213Abstract: The present invention relates to methods of gene expression profiling for inflammatory bowel disease pathogenesis, in which the differential expression in a test sample from a mammalian subject of one or more IBD markers relative to a control is determined, wherein the differential expression in the lest sample is indicative of an IBD in the mammalian subject from which the lest sample was obtained.Type: ApplicationFiled: November 26, 2008Publication date: January 7, 2010Inventors: Alexander R. Abbas, Hilary Clark, Lauri Diehl, Charles Lees, Colin L. Noble, Jack Satsangi
-
Publication number: 20090325921Abstract: A method is described herein for improving the overall health of a patient by providing a topical DHEA cream and applying the topical DHEA cream to at least one part of a body. In another embodiment, the topical DHEA cream is mixed with a moisturizing lotion and the resulting DHEA/lotion mixture is applied to at least one part of a body. In yet another embodiment, the topical DHEA cream is mixed with a sulfate lotion and the resulting DHEA/sulfate lotion combination is applied to at least one part of a body.Type: ApplicationFiled: June 23, 2009Publication date: December 31, 2009Inventor: John R. Woodward
-
Publication number: 20090325919Abstract: The invention relates to a method of preparation of a soluble formulation of water-insoluble pentacyclic and tetracyclic terpenoids, wherein the water-insoluble terpenoid having a free carboxylic, hydroxy or amino functional group is derivatized on this functional group with a substituent selected from the group comprising substituents of general formula Xa bound to the hydroxy group of the terpenoid, wherein Xa is —OC—R—COOH, substituents of general formula Xa bound to the amino group of the terpenoid, wherein Xa is —OC—R—COOH, quarternary ammonium substituents of general formula Xb bound to the carboxy group of the terpenoid, wherein Xb is —(CH2)nN+R3Y—, quarternary ammonium substituents of general formula Xc bound to the carboxy group of the terpenoid, wherein Xc je —(CH2)nR+Y—, substituents of general formula Xd bound to the carboxy group of the terpenoid, wherein Xd represents —R—COOH, glycosylic substituents Xe bound by alpha or beta glycosidic bond to the hydroxy group or to the carboxy group of the teType: ApplicationFiled: September 25, 2007Publication date: December 31, 2009Applicant: UNIVERZITA KARLOVA V PRAZE PRIRODOVEDECKA FAKULTAInventors: Jan Sarek, Marian Hajduch, Michal Svoboda, Katerina Novakova, Pavia Spacilova, Tomas Kubelka, David Biedermann
-
Publication number: 20090318398Abstract: The present invention relates to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a depressive disorder, or the symptoms associated with, or related to a depressive disorder in a subject in need thereof. The present invention also relates to a method of administering a steroid in the testosterone synthetic pathway, for example testosterone, to a subject in need thereof. In addition, the methods, kits, combinations and compositions may be used in conjunction with other pharmaceutical agents including agents effective at treating, preventing, or reducing the risk of developing a depressive disorder in a subject.Type: ApplicationFiled: August 19, 2009Publication date: December 24, 2009Applicants: Unimed Pharmaceuticals, LLC., Besins Healthcare, Inc.Inventors: Robert E. Dudley, Dominique Drouin
-
Publication number: 20090311327Abstract: The present, invention provides an oral delivery system for a therapeutic compound that is an acid, a salt of an acid or an unionized compound or a proactive form thereof with pharmacological, physiological or biochemical activity. The present invention particularly provides a swallow formulation comprising a therapeutic compound that is an acid, a salt of an acid or an unionized compound or a proactive form thereof which facilitates the rapid delivery of the therapeutic compound to the circulatory system.Type: ApplicationFiled: November 28, 2006Publication date: December 17, 2009Applicant: IMAGINOT PTY LTDInventors: Michael Stephen Roberts, George Alexander Davidson, Ruoying Jiang, Geraldine Ann Elliott, Keivan Bezanehtak, Stephen Douglas Chandler, Greg Davey, Mantu Sarkar
-
Publication number: 20090311312Abstract: A transdermal hormone delivery system (THDS) is disclosed. The THDS is useful for control of fertility and as therapy for a variety of diseases and conditions treatable by robust delivery of progestin and estrogen hormones, particularly the progestin, levonorgestrel. The THDS comprises a backing layer, an adjoining adhesive polymer matrix comprising an effective amount of at least a progestin hormone, delivery of which is enhanced by one or more skin permeation enhancing agents present in pre-determined amounts. The THDS is capable of providing effective daily doses of progestin and estrogen hormones from a small surface area in contact with the skin, e.g., less than 20 square centimeters. Methods of fertility control and various types of hormone replacement therapy utilizing the THDS are also disclosed.Type: ApplicationFiled: August 19, 2009Publication date: December 17, 2009Inventor: Te-Yen Chien
-
Patent number: 7628978Abstract: Stabilized dispersions are provided for the delivery of a bioactive agent to the respiratory tract of a patient. The dispersions preferably comprise a plurality of perforated microstructures dispersed in a suspension medium that typically comprises a hydrofluoroalkane propellant. As density variations between the suspended particles and suspension medium are minimized and attractive forces between microstructures are attenuated, the disclosed dispersions are particularly resistant to degradation, such as, by settling or flocculation. In particularly preferred embodiments, the stabilized dispersions may be administered to the lung of a patient using a metered dose inhaler.Type: GrantFiled: August 19, 2003Date of Patent: December 8, 2009Assignee: Novartis Pharma AGInventors: Jeffry G. Weers, Ernest G. Schutt, Luis Dellamary, Thomas E. Tarara, Alexey Kabalnov
-
Publication number: 20090297477Abstract: The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, including post-partum auto immune diseases) and more particularly. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor active agents to prevent or ameliorate clinical symptoms of these ThI-mediated (cell-mediated) autoimmune diseases known to either have an initial onset following the birth of a child or which are exacerbated in patients in the postpartum period.Type: ApplicationFiled: September 26, 2006Publication date: December 3, 2009Inventor: Rhonda Voskuhl
-
Publication number: 20090298742Abstract: A process for forming crystalline lactose suitable for use in a pharmaceutical formulation comprises subjecting a solution comprising a plurality of nanosized lactose particles to conditions sufficient to cause crystallization to occur on the nanosized lactose particles such that a plurality of lactose particles are formed therefrom having a median diameter ranging from about 4 ?m to about 20 ?m.Type: ApplicationFiled: August 8, 2007Publication date: December 3, 2009Applicant: GLAXO GROUP LIMITEDInventors: Trevor Charles Roche, Marian Wladyslaw Wood-Kaczmar, Xiang Tai, Michiel Van Oort
-
Publication number: 20090291929Abstract: The invention provides for compounds having formula (1) wherein; R1 is O, (H,H), (H,OH), or NOR, with R being hydrogen, (C1-6) alkyl or (C1-6) acyl; R2 is hydrogen, methyl, ethyl, or ethenyl; R3 is hydrogen, methyl, ethyl, ethenyl, fluoro, or chloro; R4 is methyl, or ethyl; R5 is hydrogen, methyl, or ethyl; R6 is hydrogen, methyl, ethyl, (C1-3) alkenyl, or (C1-3) alkynyl; R7 is hydrogen or (C1-15) acyl; and at least one of R5 or R6 is hydrogen; or a pharmaceutically acceptable salt thereof, for use as medicine for a treatment to increase androgen levels, for androgen supplementation, for testosterone replacement and for benign prostate hypertrophy and in a method of male contraception, preferably as sole means to achieve both progestagenic sterilitant effect and androgen supplementation.Type: ApplicationFiled: June 16, 2006Publication date: November 26, 2009Applicant: N.V. ORGANONInventors: Jaap Van Der Louw, Dirk Leysen, Marcel Evert De Gooijer, Joseph Maria Gerardus Barbara Cals